Clinical Trial Protocol
Iranian Registry of Clinical Trials

07 Nov 2026

comparison of efficacy of extended release venlafaxine versus sertraline in treatment of patient with major depression disorder

Protocol summary

Summary

The purpose of this study was to compare the sertraline vs. extended release venlafaxine in major depression. This randomized clinical trial was performed in Golestan Hospital, Ahvaz. In this study, 34 patients who complained of major depressive disorder were randomly allocated into two groups (16 patients in sertraline group and 18 subjects in venlafaxine group) to receive flexible dose of sertraline or extended release venlafaxine for 4 weeks. Participants should be Fulfilled DSM IV,TR criteria for major depressive disorder and excluded if they were axis I and II comorbidity, suicidal or killing thoughts. Extended-release venlafaxine was initiated with 75 mg and increased 37.5 mg each three days up to 375 mg based on patients' tolerance and response. Sertraline was initiated with 25 mg and increased 25 mg each three days up to 200 mg based on patients' tolerance and response. Depression severity was assessed, through standard Hamilton's depression questionnaire, baseline,before intervention, 2 and 4 weeks after the intervention.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2017011631626N3**
Registration date: **2017-03-21, 1396/01/01**
Registration timing: **registered_while_recruiting**

Last update:
Update count: **0**

Registration date

2017-03-21, 1396/01/01

Registrant information

Name

Hatam Boostani

Name of organization / entity

Ahvaz Jundishapur University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 61 3374 3038

Email address

tabibi.y@ajums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research Ahvaz Jundishapur University of Medical Sciences

Expected recruitment start date

2017-02-19, 1395/12/01

Expected recruitment end date

2017-05-22, 1396/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

comparison of efficacy of extended release venlafaxine versus sertraline in treatment of patient with major depression disorder

Public title

comparison of efficacy of extended release venlafaxine versus sertraline in treatment of patient with major depression disorder

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: age more than 18 years old;Fulfilled DSM IV TR criteria for major depressive disorder Baseline score 18 on the HDRS 17 Exclusion criteria: Lack of serious health problems including disease axis I and II

comorbidity ; suicidal or killing thoughts ;pregnancy;Severe physical problems and unstable

Age
From **18 years** old to **40 years** old

Gender
Both

Phase
2-3

Groups that have been masked
No information

Sample size
Target sample size: **30**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Parallel

Other design features
Randomization was done by random number table

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ethics committee of Ahvaz Jundishapur University of Medical Sciences

Street address
Ahvaz Golestan Hospital,Golestan Blvd,Ahvaz

City
Ahvaz

Postal code

Approval date
2015-04-29, 1394/02/09

Ethics committee reference number
IR.Ajums.REC.1394

Health conditions studied

1

Description of health condition studied
Depression

ICD-10 code
F32,F33

ICD-10 code description
Depressive episode

Primary outcomes

1

Description
Depression

Timepoint
before intervention, 2, 4, 6 weeks after treatment

Method of measurement
Hamilton Rating Scale for Depression

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group1: Venlafaxine extended release (75 and 150 mg capsules) at a dose of 75 mg every 3 days starts and are added 37.5 mg.And based on the response and tolerance of side effects, the dose will be increased up to 375 mg.

Category
Treatment - Drugs

2

Description
Intervention group2: Sertraline (100 and 50 mg tablets) starts once daily at a dose of 25 mg and gets added 25 mg every 3 days. And based on the response and tolerance of side effects will increase the dose up to 200 mg.

Category
Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center
Ahvaz Golestan Hospital

Full name of responsible person
Hatam Boostani

Street address
Ahvaz Golestan Hospital ,Golestan Blvd,Ahvaz

City
Ahvaz

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Vice chancellor for research Ahvaz Jundishapur University of Medical Sciences

Full name of responsible person
Hatam boostani

Street address

Ahvaz Golestan Hospital ,Golestan Blvd, Ahvaz

City

Ahvaz

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research Ahvaz Jundishapur University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Ahvaz Jundishapur University of Medical Sciences

Full name of responsible person

Hatam Boostani

Position

Assistant Professor

Other areas of specialty/work

Street address

Ahvaz Golestan hospital,Golestan Blvd,Ahvaz

City

Ahvaz

Postal code

Phone

+98 61 3374 3038

Fax

Email

Boostani_h@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Ahvaz Jundishapur University of Medical Sciences

Full name of responsible person

Hatam Boostani

Position

Assistant Professor

Other areas of specialty/work

Street address

Ahvaz Golestan Hospital,Golestan Blvd, Ahvaz

City

Ahvaz

Postal code

Phone

+98 61 3374 3038

Fax

Email

Boostani_h@yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Ahvaz Jundishapur University of Medical Sciences

Full name of responsible person

Amir ali moghadam sadegh

Position

General Practitioner

Other areas of specialty/work

Street address

Ahvaz Jundishapur University of Medical Sciences,Golestan Blvd,Ahvaz

City

Ahvaz

Postal code

Phone

+98 61 3374 3038

Fax

Email

dr_amiralimoghaddam@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty